Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Noted Executives and Entrepreneurs, Appointed as Advisors and Observers to the Board of Directors of Athos Therapeutics

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Athos Therapeutics, Inc. (the “Company”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today that Yiannis Monovoukas, Ph.D., MBA, and Monte Stettin were appointed as advisors and observers to the Board of Directors of Athos Therapeutics.

“I am delighted to join the Athos Board of Directors as an observer,” said Dr. Monovoukas. “This is an exciting time for Athos as we’re about to begin a first-in-human clinical trial with the company’s lead molecule with applications across different autoimmune diseases and cancer. The Athos team has developed an impressive platform technology and I look forward to assisting them with future strategic options.”

“It is a great privilege to join the Athos team in an advisory role and join as a Board of Directors Observer,” said Mr. Stettin. “Athos has an extraordinary corporate culture, and a team that works nimbly, doing in months what takes others years to achieve. Their leadership, team, and boards are top-notch and function in unity with great mutual respect and seamless cooperation. This is a company that will be highly disruptive and make history.”

“Dr. Monovoukas is a highly experienced and successful entrepreneur and Mr. Stettin is advising us on the development and expansion of our computational platform. Both have strong business acumen and it is our pleasure and honor to have them as advisors to our board,” said Dimitrios Iliopoulos, Ph.D., MBA, President & CEO.

“We are very pleased to welcome Yiannis Monovoukas and Monte Stettin as observers to our Board of Directors,” said Allan Pantuck, MD, MS, FACS, Chairman, Founder & CMO. “Both of these valuable additions bring to our Board decades of experience at the intersection of technology and life sciences, including in the commercialization of new therapeutics. Their expertise will be invaluable as Athos moves into the clinical and commercialization phases of development.”
About Mr. Stettin:

Monte Stettin is the Founder and CEO of Mahler Development Company as well as an advisor to a number of businesses and philanthropies. Mr. Stettin is a C class executive and entrepreneur with a career spanning publishing, advertising, entertainment and media, real estate development, design, invention, alternative energy, medical devices, software, and healthcare with a strong interest in exponential technologies and their deployment to improve the lives of the bottom billions. Monte is a benefactor of Singularity University, public speaker, connector, and change agent residing in Beverly Hills California.
About Dr. Monovoukas:

Yiannis Monovoukas, Ph.D., MBA, is the Founder, President, and CEO of Helios Cardio Inc., the co-founder and Managing Partner at SpringTide Investments, and the co-founder and Managing Partner at Falcon III Ventures. Dr. Monovoukas was previously the co-founder, President, and CEO of AuraGen Aesthetics, the Chairman, President, and CEO of TEI Biosciences, and the President and CEO of Thermo Fibergen. Yiannis holds an MBA from Harvard Business School and a PhD in Chemical Engineering from Stanford University. Dr. Monovoukas was the winner of the prestigious Ernst & Young Entrepreneur of The Year® 2011 Award for New England in Life Sciences and was a 2011 Life Sciences US National Finalist.
About Athos:

The Mission of Athos Therapeutics is to develop first-in-class medications that will significantly impact the lives of patients with autoimmune disorders, chronic inflammatory diseases, and cancer. Athos is a late-stage preclinical biotech company developing small molecule therapeutics for immune-mediated diseases and cancer using artificial intelligence-generated innovative chemistry and computational platforms.

The co-founders of Athos Therapeutics include one of the founders of Kite Pharma (acquired for $12B), the medicinal chemist behind two multi-billion-dollar FDA-approved drugs (Xtandi & Erleada), and the discoverer of the miR-124 drug target, currently in a Phase III IBD trial. Athos identifies novel drug targets (hubs) by integrating clinical and molecular datasets into the biological network of a disease (the disease interactome) and matches them to its small molecule computational chemistry platform. ATH-63, the Company’s lead drug compound, is moving into a Phase Ia human clinical trial in 2022. The Athos pipeline includes small molecule approaches for various autoimmune disease and cancer.


Other executives on the move can be found here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine